Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | BRD1 | O95696 | 1/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546223 | 0.93 | DRD2 (0.46) | DRD2DRD3KCNH2KMT2ATRIM24 | |
| SCHEMBL1546251 | 0.85 | DRD2 (0.44) | DRD2DRD3KCNH2KMT2ATRIM24 | |
| SCHEMBL1546424 | 0.83 | DRD2 (0.56) | DRD2DRD3KCNH2KMT2ATRIM24 | |
| SCHEMBL1546284 | 0.82 | SLC2A1 (0.45) | DRD2DRD3KCNH2KMT2ATRIM24 | |
| SCHEMBL1547010 | 0.81 | TP53 (0.46) | DRD2DRD3KCNH2ALDH1A1LMNA | |
| SCHEMBL5574232 | 0.81 | DRD2 (0.43) | DRD2DRD3KCNH2KMT2ATRIM24 | |
| SCHEMBL4688582 | 0.80 | KMT2A (0.48) | DRD2DRD3KCNH2KMT2ATRIM24 | |
| SCHEMBL1546189 | 0.80 | BCHE (0.48) | ALDH1A1LMNASLC2A1 | |
| SCHEMBL15061259 | 0.78 | KDM2B (0.53) | DRD2DRD3KCNH2KMT2ATRIM24 | |
| SCHEMBL5574178 | 0.78 | DRD2 (0.52) | DRD2DRD3KCNH2KMT2ATRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470810-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-06-30 | — | — | US | disclosed |
| EP-2311802-A1 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311803-A1 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1814849-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-04-06 | — | — | EP | disclosed |
| US-7851463-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, CHRNA3, CHRM3 | DRD2 17/4885DRD3 1/4885KCNH2 522/4885 |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | DRD2 13/4885DRD3 1/4885KCNH2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.